TCID is a novel potent and selective inhibitor of ubiquitin C-terminal hydrolase-L3 (UCH-L3) with an IC₅₀ ~0.6 μM. It has ~125-fold greater selectivity over UCH-L1 (ubiquitin C-terminal hydrolase L1, IC₅₀ ~75 μM). TCID can diminish glycine transporter GlyT2 ubiquitination in brain stem and spinal cord primary neurons.

How to Use:

• In vitro: TCID was used at 10-30 µM final concentration in various in vitro assays.
• In vivo: n/a

Reference:

1. 1. Liu Y, et al. Discovery of inhibitors that elucidate the role of UCH-L1 activity in the H1299 lung cancer cell line. (2003) Chem Biol. 10(9):837-46.
2. 2. de Juan-Sanz J, et al. Constitutive endocytosis and turnover of the neuronal glycine transporter GlyT2 is dependent on ubiquitination of a C-terminal lysine cluster. (2013) PLoS One. 8(3):e58863.